TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T-CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST-HOC ANALYSIS OF THE MAVORIC STUDY
-
Kim, Y.H.
Dermatology; Stanford University School of Medicine; Stanford United States
-
Ortiz-Romero, P.L.
Dermatología; Institute i+12, Hospital Universitario 12 de Octubre, Universidad Complutense; Madrid Spain
-
Pro, B.
Oncology; Northwestern University; Chicago United States
-
Sokol, L.
Hematology/Oncology; H. Lee Moffitt Cancer Center; Tampa United States
-
Scarisbrick, J.
Lymphoma Service; University Hospitals Birmingham; Birmingham United Kingdom
-
Musiek, A.
Dermatology; Washington University; St. Louis United States
-
Vermeer, M.
Dermatology; Leiden University Medical Center; Leiden Netherlands
-
Dummer, R.
Dermatology; UniversitatsSpital Zurich; Zurich Switzerland
-
Halwani, A.
Hematology; University of Utah; Salt Lake City United States
-
Fierro, M.
Scienze Mediche; Università di Torino; Torino Italy
-
Moriya, J.
Biostatistics; Kyowa Kirin Pharmaceutical Development, Inc.; Princeton United States
-
Leoni, M.
Medical Sciences; Kyowa Kirin Pharmaceutical Development, Inc.; Princeton United States
-
Bagot, M.
Service de Dermatologie; Hôpital Saint Louis, APHP, Inserm U976, Université Paris 7; Paris France
Show more…
Published in:
- Hematological Oncology. - Wiley. - 2019, vol. 37, p. 285-286
-
Language
-
-
Open access status
-
bronze
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/121048
Statistics
Document views: 33
File downloads: